1. Show article details.

    BRIEF-Harpoon Therapeutics Granted Orphan Drug Designation From FDA For Hpn217 For Treatment Of Multiple Myeloma

    Reuters – 10:29 AM ET 01/13/2021

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS GRANTED ORPHAN DRUG DESIGNATION FROM FDA FOR HPN217 FOR TREATMENT OF MULTIPLE MYELOMA. * Harpoon Therapeutics Inc (HARP) - HPN217 HAS BEEN WELL TOLERATED, AND NO DLTS HAD BEEN OBSERVED AS OF MOST RECENT DECEMBER 1, 2020 DATA CUTOFF DATE.

  2. Show article details.

    Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma

    GlobeNewswire – 7:30 AM ET 01/13/2021

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for HPN217 for the treatment of multiple myeloma.

  3. Show article details.

    BRIEF-Harpoon Announces Closing Of Public Offering Of Common Stock

    Reuters – 4:40 PM ET 01/11/2021

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

  4. Show article details.

    Harpoon Therapeutics Announces Closing of Public Offering of Common Stock

    GlobeNewswire – 4:01 PM ET 01/11/2021

    Harpoon Therapeutics, Inc. (HARP) announced today the closing of its underwritten public offering of 6,764,704 shares of its common stock, which includes 882,352 shares sold upon the underwriters’ full exercise of their option to purchase additional shares, resulting in aggregate gross proceeds of approximately $115.0 million, before deducting underwriting discounts and commissions and offering expens...

  5. Show article details.

    BRIEF-Harpoon Therapeutics Announces Offering Of 5.9 Mln Shares At $17.00 Per Share

    Reuters – 9:48 PM ET 01/06/2021

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK. * ANNOUNCED PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 5,882,352 SHARES OF ITS COMMON STOCK AT $17.00 PER SHARE Source text for Eikon: Further company coverage:

  6. Show article details.

    Harpoon Therapeutics Announces Pricing of Public Offering of Common Stock

    GlobeNewswire – 9:44 PM ET 01/06/2021

    Harpoon Therapeutics, Inc. (HARP), announced today the pricing of an underwritten public offering of 5,882,352 shares of its common stock at a price to the public of $17.00 per share.

  7. Show article details.

    BRIEF-Harpoon Announces Proposed Public Offering Of Common Stock

    Reuters – 4:18 PM ET 01/06/2021

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

  8. Show article details.

    Harpoon Therapeutics Announces Proposed Public Offering of Common Stock

    GlobeNewswire – 4:01 PM ET 01/06/2021

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it has commenced an underwritten public offering of its common stock.

  9. Show article details.

    BRIEF-Harpoon Therapeutics Doses First Patient With HPN328, For Treatment Of Small Cell Lung Cancer, Other DLL3-Associated Tumors

    Reuters – 7:58 AM ET 01/04/2021

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN328, AN ANTI-DLL3 T CELL ENGAGER FOR TREATMENT OF SMALL CELL LUNG CANCER AND OTHER DLL3-ASSOCIATED TUMORS Source text for Eikon: Further company coverage:

  10. Show article details.

    Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors

    GlobeNewswire – 7:30 AM ET 01/04/2021

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the first patient has been dosed with HPN328, a delta like ligand 3- targeting TriTAC®, in a Phase 1/2 clinical trial as an investigational treatment of small cell lung cancer and other tumors associated with DLL3 expression.

  11. Show article details.

    BRIEF-Harpoon Reports Clinical Progress Across All Four TriTAC Pipeline Development Programs

    Reuters – 8:50 AM ET 12/08/2020

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS (HARP) - HPN424 SHOWN PARTIAL RESPONSE IN TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN HIGHEST FIXED DOSE COHORT. * Harpoon Therapeutics Inc (HARP) - THREE OF SEVEN PATIENTS IN HIGHEST FIXED DOSE HPN424 COHORT HAVE SHOWN PSA REDUCTION. * Harpoon Therapeutics Inc (HARP) - DOSE ESCALATION TRIALS ADVANCING FOR HPN536 AND HPN217.

  12. Show article details.

    Harpoon Therapeutics Reports Clinical Progress Across All Four TriTAC® Pipeline Development Programs

    GlobeNewswire – 8:00 AM ET 12/08/2020

    HPN424 has shown confirmed partial response in treatment of metastatic castration-resistant prostate cancer in highest fixed dose cohort of continuing Phase 1/2a dose escalation trial Three of seven patients in highest fixed dose HPN424 cohort have shown PSA reduction Dose escalation trials advancing for HPN536 and HPN217 with initial data readouts and initiation of expansion cohorts expected ...

  13. Show article details.

    Harpoon Therapeutics to Host Clinical Pipeline Programs Update Call and Webcast on December 8, 2020

    GlobeNewswire – 4:05 PM ET 12/07/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it will host a conference call and webcast to review the status and provide a clinical update for its three most advanced TriTAC® programs.

  14. Show article details.

    Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference

    GlobeNewswire – 7:30 AM ET 11/16/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference, being held December 1-3, 2020.

  15. Show article details.

    BRIEF-Harpoon Therapeutics Presents Preclinical Data On HPN601

    Reuters – 4:48 PM ET 11/12/2020

    Harpoon Therapeutics Inc (HARP): * Harpoon Therapeutics Inc (HARP) - PRESENTED PRECLINICAL DATA ON HPN601 FOR TREATMENT OF SOLID TUMORS Source text for Eikon: Further company coverage:

  16. Show article details.

    Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EpCAM ProTriTAC™ Program at 35th SITC Annual Meeting

    GlobeNewswire – 4:15 PM ET 11/12/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented preclinical data on HPN601 for the treatment of solid tumors at the 35th Society for Immunotherapy of Cancer virtual annual meeting.

  17. Show article details.

    Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

    GlobeNewswire – 7:30 AM ET 11/09/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences: A live audio webcast of the Stifel presentation will be available in the Investors section of Harpoon Therapeutics’ website at www.harpoont...

  18. Show article details.

    BRIEF-Harpoon Abstract For HPN601 EpCAM ProTriTAC Program Accepted For Oral Presentation

    Reuters – 8:16 AM ET 11/05/2020

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS ABSTRACT FOR HPN601 EPCAM PROTRITAC™ PROGRAM ACCEPTED FOR ORAL PRESENTATION AT UPCOMING 35TH SITC ANNUAL MEETING Source text for Eikon: Further company coverage:

  19. Show article details.

    Harpoon Therapeutics Abstract for HPN601 EpCAM ProTriTAC™ Program Accepted for Oral Presentation at Upcoming 35th SITC Annual Meeting

    GlobeNewswire – 7:30 AM ET 11/05/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing novel T cell engagers, announced today that the preclinical data on HPN601 for the treatment of solid tumors has been accepted for oral presentation at the 35th Society for Immunotherapy of Cancer annual meeting.

  20. Show article details.

    BRIEF-Harpoon Therapeutics Reports Third Quarter 2020 Financial Results And Provides Corporate Update

    Reuters – 4:18 PM ET 11/04/2020

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE. * Q3 REVENUE $3.9 MILLION VERSUS $1.4 MILLION. * Q3 REVENUE ESTIMATE $5.5 MILLION -- REFINITIV IBES DATA. * QTRLY LOSS PER SHARE $0.53. * Q3 EARNINGS PER SHARE VIEW $-0.50 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

Page:

Today's and Upcoming Events

  • Mar
    10

    HARP to announce Q4 earnings (Unconfirmed)

Past Events (last 90 days)

  • Nov
    04

    HARP announced Q3 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.